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{3-lactam Antibiotics Active against Methicillin-
Resistant Staphylococcus aureus
To THE Enrroa-e-Chambersand Sachdeva[1]recentlysuggested that
the in vitro susceptibility of two test strains of methicillin-resistant
Staphylococcus aureus (MRSA) to a series of 13-lactam antibiotics
correlates well with the avidity of the drugs to bind to penicillin-
binding protein (PBP) 2a, the Iow-ti-lactam-affinity PBP produced
by these organisms. These findings confirm comparable observa-
tions made earlier in our laboratory [2]. Also, recent genetic evi-
dence [3] clearly implies a quantitative contribution of PBP 2a to
the MIC values of 13-1actams for MRSA: selective transposon inac-
tivationof the PBP 2a gene resulted in a massivedrop in MIC values
of methicillin, from 1000 to 4 mg/I.
Mostclinicalisolatesof MRSAproducepenicillinase, and13-lactam
antibiotics of potential clinical use against MRSA must be able to
resist enzymaticdegradation as wellas havinggood PBP2a affinity.
Alternatively, a penicillinase-susceptible 13-lactam with relatively
good PBP 2a affinitycan be combined with penicillinase inhibitors
such as clavulanate or sulbactam. Indeed, in some in vitro experi-
ments by Chambers et al. [4] and in earlier studies by others [2,
5-7], drug combinations suchas ampicillin withsulbactamand amox-
icillinwith clavulanateshowedrelativelylowMIC valuesfor MRSA
strains. Surprisingly,however, ampicillinand sulbactamcured only
30% of MRSA infections when tested in vivo in the rabbit model
of experimentalendocarditis [4]. Thesedisappointing resultsare also
in sharp contrast with the high rate of successfultreatment observed
in in vivo experiments reported earlier from our laboratory [6, 7]
usingthe rat model andbyWashburnet al. [5]usingthe rabbit model
of endocarditis. In both laboratories, amoxicillin with clavulanate
or ampicillin with sulbactam successfully treated ~80% of the
animals, a result equal or superior to that obtained with vancomycin
in an identical experimental setting in rats.
The discrepancybetween in vivo observationsof Chambers et aI.
[4] and the successful in vivo experiments reported earlier [5-7] re-
quires an explanation. On the basis of the poor in vivo performance
of ampicillin and sulbactam (and some other (3-lactams), Chambers
et al. [4]expresspessimismconcerning thechemoptherapeutic poten-
tial of 13-lactam antibiotics currently in clinical use. We disagree:
Webelieve an appropriate increase in the concentrations of the an-
tibiotic and penicillinase inhibitor easily achievableunder clinical
conditions could make this combination therapy a highly relevant
andeconomicallyfeasible alternativetreatmentfor MRSAinfections.
While the larger numbers of bacteria on the infected vegetations
at the beginning of treatment in rabbits compared with that in rats
may havecontributed to the differentoutcome of these experiments
[4,5-7], it seems that the critical differencehas to do with the dos-
age of the drugs. We recently observed (using the rat model) that
the therapeutic efficacy of amoxicillin and clavulanate closely cor-
related with the dosageof the penicillinaseinhibitor clavulanate[7].
In a typical experiment, successfultreatment of endocarditiscaused
by penicillinase-producingMRSAincreased from 30%to 70%and
.>90% simply by increasing by two and five times, respectively, the
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proportion of clavulanate in the antibiotic regimen. When an iso-
genicpenicillinase-negative derivative of the sameMRSA strain (i.e.,
the original strain cured of its penicillinase plasmid in the labora-
tory) was used in the rat model, amoxicillin given alone success-
fully treated >90% of endocarditis. Amoxicillin is known to have
relativelygood PBP 2a affinity [1, 2]. Using the same penicillinase-
negativeMRSA, we found that cloxacillin at higher concentrations
than amoxicillincould not achieve cure. Cloxacillin, in contrast to
amoxicillin, has poor binding capacity to PBP 2a.
Even more significant were our tests in which the highly and
homogeneouslyresistant (free of penicillinase) MRSA strain COL
[8] was used to produce experimental endocarditis in rats. Amox-
icillingivenaloneresultedin >90%successful treatmenteventhough
there were high numbers of bacteria on the infected valves and all
were expressing high resistance levels at the beginning of antibio-
therapy [7].
Takentogether, these data cause us to draw a conclusionopposite
to that of Chambers et aI. ,8-lactam antibiotics with relatively good
affinityfor PBP 2a, whenapplied at appropriateconcentrations,can
be quite effective against MRSA strains both in vitro and in vivo.
Such 13-lactams are available, as are effective penicillinase inhibi-
tors. The combination of these agents may provide an important
chemotherapeutic alternative that should not be overlooked when
designing curing regimens against MRSA infections.
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